Merck Eyes Molnupiravir for Ebola as Lung-Cancer Rival Faces Skepticism
MRK•Merck is in talks with global health authorities to repurpose its oral antiviral molnupiravir for the Ebola outbreak in DRC, involving 1,100 suspected cases and 42 fatalities. Investors have shown muted response to early results on a potential Keytruda-replacing lung cancer candidate, underscoring doubts about its commercial prospects.
1. Molnupiravir Ebola Discussions
Merck’s chief medical officer confirmed ongoing discussions with multiple global health authorities to deploy molnupiravir, sold as Lagevrio, against the Bundibugyo strain of Ebola in the Democratic Republic of Congo. The outbreak has logged around 1,100 suspected infections and 42 deaths, and molnupiravir’s broad-spectrum antiviral properties seen in animal studies could fill a treatment gap where no approved therapies exist.
2. Investor Reaction to Lung-Cancer Candidate
An experimental lung-cancer therapy positioned as a potential successor to Keytruda failed to excite investors, with preliminary data releases prompting only a muted market response. Skepticism centers on the therapy’s ability to match Keytruda’s efficacy and market dominance, raising questions about its commercial viability.
